2021 San Antonio Breast Cancer Symposium
Scientific Contributions
• 15 Abstracts accepted for poster presentation.
• 2 Abstracts accepted for Spotlight Poster Discussions.
• 2 General Session presentations
GENERAL SESSION PRESENTATIONS
• GS1-05
Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study
Krop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, Lisberg AE, Kogawa T, Papadopoulos KP, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F, Bardia A. Dana-Farber Cancer Institute, Boston, MA; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center Harvard Medical School, Boston, MA; National Cancer Center Hospital, Tokyo, Japan; NEXT Oncology, San Antonio, TX; Virginia Cancer Specialists, Fairfax, VA; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA; Advanced Medical Development Center, Cancer Institute Hospital of JFCR, Tokyo, Japan; START Center for Cancer Care San Antonio, San Antonio, TX; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Daiichi Sankyo Inc, Basking Ridge, NJ; Daiichi Sankyo Co, Ltd, Tokyo, Japan
• GS4-10.
Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial
Jhaveri K, Park H, Waisman J, Goldman JW, Guerrero-Zotano A, Boni V, Haley B, Mayer IA, Brufsky A, Yang ES, García-Sáenz JA, Bidard F-C, Crown J, Zhang B, Frazier A, Diala I, Eli LD, Barnett B, Wildiers H. Memorial Sloan Kettering Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; City of Hope Comprehensive Cancer Center, Duarte, CA; UCLA, Santa Monica, CA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; START Madrid-CIOCC, Hospital Universitario, Madrid Sanchinarro, Madrid, Spain; UT Southwestern Medical Center, Dallas, TX; Vanderbilt University Medical Center / Vanderbilt-Ingram Cancer Center, Nashville, TN; Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Alabama at Birmingham, Birmingham, AL; Hospital Clínico San Carlos, Madrid, Spain; Institut Curie, St. Cloud, France; St. Vincent’s University Hospital, Dublin, Ireland; Puma Biotechnology Inc., Los Angeles, CA; University Hospitals Leuven, Leuven, Belgium.
POSTER PRESENTATIONS
P1-17-11
Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer Chandarlapaty S, Linden HM, Neven P, Petrakova K, Bardia A, Kabos P, Braga S, Boni V, Gosselin A, Celanovic M, Cohen P, Paux G, Pelekanou V, Ternès N, Lee JS, Campone M. Memorial Sloan Kettering Cancer Center, New York, NY; University of Washington Medical Center, Seattle Cancer Care Alliance, Seattle, WA; Universitair Ziekenhuis Leuven, Leuven, Belgium; Masarykuv Onkologický Ustav, Brno, Czech Republic; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of Colorado Denver, Aurora, CO;; Instituto CUF de Oncologia, Lisbon, Portugal; START Madrid-Centro, Madrid, Spain; Sanofi, Paris, France; Sanofi, Cambridge, MA; Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France.
P2-13-07
Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study Bedard PL, Im S-A, Elimova E, Rha SY, Goodwin R, Ferrario C, Lee K-W, Hanna D, Meric-Bernstam F, Mayordomo J, Beeram M, Hamilton E, Chaves J, Cobleigh M, Mwatha T, Woolery J, Oh D-Y. Princess Margaret Cancer Centre, Toronto, ON, Canada; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; University of Ottawa Cancer Centre, Ottowa, ON, Canada; Jewish General Hospital da, Montréal, QC, Canada; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; USC Norris Comprehensive Cancer Center, Los Angeles, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Aurora, CO; The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Northwest Medical Specialists, Tacoma, WA; Rush University Medical Center, Chicago, IL; Zymeworks Inc., Vancouver, BC, Canada.
P5-01-04
Correlation of HER2 receptor expression and in vivo activity of the HER2-targeting therapies trastuzumab deruxtecan (DS-8201a) and T-DM1 activity in a panel of breast XPDX models Simonson A, Forofontov P, Flores JR, Hernandez K, Cabang A, Lang A, Rodriguez G, Papadopoulos K, Beeram M, Rosenthal A, DeBerry B, Smith L, Drengler R, Patnaik A, Rasco D, Rodriguez L, Abbate S, Ulmer S, Wick M. XenoSTART, San Antonio, TX; START Center, San Antonio, TX; START, San Antonio, TX.
P5-01-06
Establishment and characterization of luminal A breast XPDX models from patients with acquired resistance to CDK 4/6 inhibitors Hernandez T, Kneifel D, Simonson A, Flores JR, Quick S, Cabang A, Ulmer A, Papadopoulos K, Lang A, Rodriguez G, Beeram M, Rasco D, Patnaik A, Ulmer S, Wick MJ. XenoSTART, San Antonio, TX; START, San Antonio, TX; START Center, San Antonio, TX
P5-01-09
Establishment and characterization of two simultaneously developed T-DM1-resistant, ER+/HER2+ XPDX models from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a) Flores JR, Stackpole A, Garza A, Ulmer A, Simonson A, Papadopoulos K, Cabang A, Ma J, Patnaik A, Rasco D, Lang A, Rodriguez G, Beeram M, Wick MJ. XenoSTART, San Antonio, TX; START, San Antonio, TX; START Center, San Antonio, TX.
P5-01-11
Nonclinical activity of fulvestrant in a panel of ER+ breast XPDX models representing clinically acquired and innate resistance to endocrine therapies Cabang A, Moreno C, Flores JR, Boedeker J, Simonson A, Ma J, Lang A, Rodriguez G, Rosenthal A, Papadopoulos K, Patnaik A, Rasco D, Smith L, Beeram M, Drengler R, Rodriguez L, Abbate S, Ulmer S, Wick MJ. XenoSTART, San Antonio, TX; START Center, San Antonio, TX; START, San Antonio, TX.
P5-16-06
A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer Yap TA, Basu C, Goldman JW, Gordon M, Hamilton E, Kelly A, Liu F, Moreau AR, Neumann H, Papadopoulos K, Rugo HS, Shapiro GI, Vinayak S, Zhou L, Jhaveri K. University of Texas MD Anderson Cancer Center, Houston, TX; Pfizer Inc, San Diego, CA; University of California Los Angeles, Los Angeles, CA; HonorHealth Research Institute, Scottsdale, AZ; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; JPK Consultants, Bethesda, MD; START San Antonio, San Antonio, TX; University of California San Francisco, San Francisco, CA; Dana Farber Cancer Institute, Boston, MA; University of Washington School of Medicine, Seattle, WA; Memorial Sloan Kettering Cancer Center, New York, NY.
P5-17-12
First-in-human expansion study of oral PMD-026 in metastatic triple negative breast cancer patients Beeram M, Wang JS, Mina LA, Chalasani P, Shatsky RA, Wesolowski R, Hurvitz SA, Trivedi MS, Han HS, Patnaik A, Huynh M-m, Jayanthan A, Pambid MR, Yue L, Los G, Dunn SE, Dorr A. START Center for Cancer Care, San Antonio, TX; Johns Hopkins Medical Institutions, Baltimore, MD; Indiana Cancer Pavillion, Indianapolis, IN; University of Arizona Cancer Center, Tucson, AZ; UCSD Medcl Ctr, San Diego, CA; The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; David Geffen School of Medicine, University of California, Los Angeles/ Jonsson Comprehensive Cancer Center, Los Angeles, CA; Columbia University Irving Medical Center, New York, NY; Moffitt Cancer Center, Tampa, FL; Phoenix Molecular Designs, Vancouver, BC, Canada; Phoenix Molecular Designs, San Diego, CA; Dorr & Associates, San Diego, CA.
P5-18-07
Heart rate changes, cardiac safety, and exercise tolerance from a phase Ia/b study of giredestrant (GDC-9545) ± palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer Neilan TG, Villanueva-Vázquez R, Bellet M, López-Miranda E, García-Estévez L, Kabos P, Bond J, Gates MR, Chang C-W Boni V. Massachusetts General Hospital, Boston, MA; ICO l’Hospitalet – Hospital Duran i Reynals, Barcelona, Spain; Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; MD Anderson Cancer Center Madrid, Madrid, Spain; University of Colorado, Aurora, CO; Genentech, Inc., South San Francisco, CA; START Madrid-CIOCC, Centro Integral Oncologico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain
OT1-12-02
Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab Miller K, Emens LA, Tolaney SM, Hurvitz SA, Hamilton E, Paton V, Hannah A, Boni V. Indiana University Simon Cancer Center, Indianapolis, IN; University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; CytomX Therapeutics, Inc., South San Francisco, CA; START Madrid CIOCC, Comprehensive Cancer Center Clara Campal, HM Universitary Hospital Sanchinarro, Madrid, Spain
OT2-01-01
Phase 1 study of ST101, a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ), in patients with advanced solid tumors, with a phase 2 expansion in patients with hormone receptor positive breast cancer (HR+ BC) Bexon AS, Arkenau H-T, Evans J, Falchook GS, Symeonides SN, McKean MA, Fontana E, Bupath M, McLaren A, Chandana S, Ding T, Lim EA, Rotolo J, Capiaux G, Michel R, Kaesshaefer S, Lakhani NJ. Sapience Therapeutics Inc., Harrison, NY; Sarah Cannon Research Institute and University College London, London, United Kingdom; University of Glasgow, Beatson West of Scotland Cancer Center, Glasgow, United Kingdom; Sarah Cannon Research Institute, Denver, CO; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom; The University of Texas MD Anderson Cancer Center, Houston, TX; Sarah Cannon Research Institute UK, London, United Kingdom; Sarah Cannon Research Institute at HealthONE, Denver, CO; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; START Midwest, Grand Rapids, MI; Columbia University-Herbert Irving Comprehensive Cancer Center, New York, NY
OT2-01-02
First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer Patnaik A, Barve M, Bhave M, Subbiah V, Atwal S, Sharma K, Scheffold C, Wetmore C, Shapiro G. START Center for Cancer Care, San Antonio, TX; Mary Crowley Cancer Research Centers, Dallas, TX; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX; Exelixis, Inc., Alameda, CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
OT2-11-02
Ameera-1 Arm 4: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with everolimus in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer Campone M, Neven P, Petrakova K, Braga S, Celanovic M, Cohen P, Gosselin A, Cartot-Cotton S, Pelekanou V, Boni V. Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France; Universitair Ziekenhuis Leuven, Leuven, Belgium; Masarykův Onkologický Ustav, Brno, Czech Republic; Instituto CUF de Oncologia, Lisbon, Portugal; Sanofi, Cambridge, MA; Sanofi, Paris, France; START Madrid-CIOCC, Centro Oncológico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain
OT2-11-03
AMEERA-1 : Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-)PIK3CA-mutated advanced breast cancer Campone M, Bardia A, Kabos P, Chandarlapaty S, Neven P, Boni V, Lord S, Cartot-Cotton S, Celanovic M, Gosselin A, Pelekanou V, Linden HM. Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of Colorado, Aurora, CO; Memorial Sloan Kettering Cancer Center, New York, NY; Universitair Ziekenhuis Leuven, Leuven, Belgium; START Madrid-CIOCC, Centro Oncológico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain; University of Oxford, Oxford, United Kingdom; Sanofi, Paris, France; Sanofi, Cambridge, MA; University of Washington Medical Center, Seattle Cancer Care Alliance, Seattle, WA
OT2-11-04
Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer Campone M, Chandarlapaty S, Bardia A, Neven P, Petrakova K, Kabos P, Boni V, Braga S, Celanovic M, Cohen P, Gosselin A, Cartot-Cotton S, Pelekanou V, Linden H. Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Universitair Ziekenhuis Leuven, Leuven, Belgium; Masarykův Onkologický Ustav, Brno, Czech Republic; University of Colorado, Aurora, CO; START Madrid-CIOCC, Centro Oncológico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain; Instituto CUF de Oncologia, Lisbon, Portugal; Sanofi, Cambridge, MA; Sanofi, Paris, France; University of Washington Medical Center, Seattle Cancer Care Alliance, Seattle, WA
PD10-04
Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC) Hurvitz SA, Boni V, Comen E, Im S-A, Jung KH, Kim S-B, Lee KS, Loi S, Rugo HS, Sonnenblick A, Telli ML, DuPree K, Fasso M, Lin Y-C, Nikanjam M, Schimmoller F, Zhang X, Zhu J, Schmid P. University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; START Madrid CIOCC, Centro Integral Oncológico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Seoul National University College of Medicine, Seoul, Republic of Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang-si, Republic of Korea; Peter MacCallum Cancer Center, Melbourne, Australia; University of California San Francisco, San Francisco, CA; Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv, Israel; Stanford Cancer Institute, Stanford University, Palo Alto, CA; Genentech, Inc, South San Francisco, CA; Barts Health NHS Trust - St Bartholomew's Hospital, London, United Kingdom.
PD13-07
Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC) Presenter: Elgene Lim Turner NC, Loi S, Moore HM, Chang C-W, Eng-Wong J, Bardia A, Boni V, Sohn J, Jhaveri KL, Lim E. Royal Marsden Hospital, London, United Kingdom; Peter MacCallum Cancer Centre, Melbourne, Australia; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Boston, MA; START Madrid-CIOCC, Centro Integral Oncologico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Memorial Sloan Kettering Cancer Center, New York, NY; Garvan Institute of Medical Research, St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Darlinghurst, Australia.
Learn more about the industry-leading research at the START Center: